Monarch Partners Asset Management’s Harvard Bioscience HBIO Stock Holding History

Monarch Partners Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.7M	Sell	61,384 -18,742	-23%	-$462K	0.5%	99
2022 Q3	$2.05M	Hold	80,126	–	–	0.62%	80
2022 Q2	$2.88M	Buy	80,126 +30,806	+62%	+$1.39M	0.81%	49
2022 Q1	$3.06M	Hold	49,320	–	–	0.68%	61
2021 Q4	$3.48M	Buy	49,320 +16,312	+49%	+$1.16M	0.71%	57
2021 Q3	$2.3M	Sell	33,008 -1,416	-4%	-$113K	0.34%	104
2021 Q2	$2.87M	Buy	+34,424	New	+$2.44M	0.41%	88
2020 Q1	–	Sell	-12,347	Closed	-$377K	–	170
2019 Q4	$377K	Hold	12,347	–	–	0.08%	162
2019 Q3	$380K	Buy	12,347 +1,463	+13%	+$36.4K	0.06%	160
2019 Q2	$218K	Hold	10,884	–	–	0.03%	165
2019 Q1	$469K	Buy	+10,884	New	+$395K	0.07%	157

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Monarch Partners Asset Management's HBIO Position: Q4 2022 in Review

Monarch Partners Asset Management reduced its Harvard Bioscience (HBIO) stake by 23% in Q4 2022, selling an estimated $462K and leaving 61,384 shares worth $1.7M. The position accounts for 0.5% of the portfolio, ranked #99.

Monarch Partners Asset Management first reported a position in HBIO in Q1 2019 and has held it in 11 quarters since. The position peaked at $3.48M in Q4 2021. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2022.

Monarch Partners Asset Management held 61,384 shares of Harvard Bioscience worth $1.7M as of Q4 2022.
Monarch Partners Asset Management sold 18,742 Harvard Bioscience shares in Q4 2022, an estimated $462K.
Harvard Bioscience made up 0.5% of Monarch Partners Asset Management's portfolio in Q4 2022, its #99 holding.
Monarch Partners Asset Management first reported a position in Harvard Bioscience in Q1 2019 and has held it in 11 quarters since.
Monarch Partners Asset Management's Harvard Bioscience position peaked at $3.48M in Q4 2021.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.